Introduction
Multidrug resistance is a property closely linked with the occurrence of treatment failure in adult acute myeloid leukemia (AML). 1, 2 One aspect of multidrug resistance observed in diseases such as AML, is effected by expression of the mdr1/pglycoprotein 170 kilodalton product. 3, 4 Historically, mdr1 was the first recognized form of such resistance, and it occurred by amplification at the chromosomal level and overexpression at the protein level in several model cell lines selected in the presence of toxic concentrations of adriamycin or other agents. [5] [6] [7] Mdr1/p-glycoprotein expresssion may also be upregulated by transcriptional mechanisms, which is the more likely clinical scenario. 8, 9 In addition, distinct members of the ABC (ATP-binding cassette) family of membrane efflux pumps, such as MRP, multidrug resistance-associated protein, are up-regulated in cells by exposure in vitro to toxic xenobiotics, and yet MRP does not function alone. 10, 11 In fact, multidrug resistance associated with MRP-mediated efflux is highly dependent upon coordinate expression of a series of non-membrane proteins whose singular overexpression is also incapable of effecting multidrug resistance. 12, 13 An evolving concept is that multidrug resistance, particularly involving MRP, may be part of a cellular homeostatic response to oxidative stress and xenobiotics. 14, 15 In this regard, MRP is joined in a functional unit by glutathione-S-transferase(s) and by glutathione (GSH), to yield cellular GS-X conjugates which are the substrates for MRP efflux. [11] [12] [13] [14] [15] [16] It has been suggested that a central cellular program involving the transcription factor c-jun/AP-1 may regulate coordinate expression of genes/products such as MRP, ␥glutamyl cysteine synthase (␥GCS) (rate limiting enzyme in glutathione synthesis), as well as glutathione-S-transferase (GST) .
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Thus, the multidrug-resistant state in cells may critically depend upon this transcriptional axis. Support for this hypothesis is provided by two model systems. First, genomic deletion within fission yeast of the homologues of c-jun and c-jun Nterminal kinase (JNK) genes renders the yeast extremely sensitive to oxidative stress, cisplatinum toxicity and incapable of expressing members of the ABC membrane efflux family. 17 In addition, those yeast fail to express thioredoxin, thioredoxin reductase and catalase. Second, human tumor cell lines express increased JNK activity upon exposure to adriamycin in a time-and drug concentration-dependent manner. 18 Further, transformation of cells, including leukemia cells, by tyrosine kinase oncogenes (which involve p21ras signaling) or by mutant p21ras, requires c-jun and JNK. [19] [20] [21] On the one hand, this requirement for JNK may reflect the generation of oxyradicals as a byproduct of p21ras signal transduction involved in transformation, and the requirement for a cellular detoxification mechanism afforded by JNK signaling to deal with this potentially toxic state. 22 Also, oncogene signaling through p21ras/raf/c-myc/arf induces block in cell cycle in naive cells, which is mediated by p53-dependent up-regulation of p21cip1, a pan-reactive cyclin-dependent kinase inhibitor. [23] [24] [25] When c-jun is activated for transcription by JNK, repression of basal p53 transcription results, and as a consequence, diminished p21cip1 expression follows, so as to allow cell cycle progression. 26, 27 The present study was undertaken to provide direct evidence for the role of c-jun phosphorylation on serines 63, 73 by JNK toward human leukemic cell multidrug resistance against the anthracycline daunorubicin/daunomycin by examination of leukemic cell lines. Secondly, the occurrence of constitutive JNK activity within freshly isolated primary human leukemia blast cells was investigated for its correlation with disease presentation and prognosis. We report here an important role for c-jun/JNK in AML cell behaviors that affect virulence of the disease and its response to treatment.
The human myelocytic leukemia cell line HL-60 was obtained from the Cell Depository of the American Type Culture Collection (ATCC, Bethesda, MD, USA). The adriamycin-resistant variant of HL-60 resulting from exposure of cells to adriamycin, HL-60/ADR, was obtained from Dr Melvin Center, Kansas State University. 28 A variant of HL-60 highly resistant to vincristine, HL-60/VCR, was also obtained from Dr Center. All of these cell lines were maintained in RPMI medium supplemented with 10% fetal calf serum (FCS). K562, a cell line from a patient with myeloid blast crisis of chronic granulocytic leukemia was also obtained from ATCC, and was passaged in McCoy's medium, supplemented with 10% FCS. Blast cells from the bone marrow of patients with acute myeloid leukemia were obtained at the time of diagnostic testing after informed consent. These cells were diluted 1:4 with Hank's balanced salt solution and layered on to Ficoll-Hypaque. After centrifugation for 30 min at 1200 r.p.m., the buoyant fraction was isolated, and then washed with phosphate-buffered saline (PBS) before processing. Those cells to be assayed directly in kinase assays (see below) were washed in ice-cold PBS with 1 mmol/l (mM) sodium orthovanadate (Na 3 VO 4 ). The cell pellet was lysed in sample buffer (20 mM TrisHCl, pH 8.0, 137 mM NaCl, 10% glycerol, 1 mM PMSF, 1 g/ml aprotonin, 2 mM EDTA, 10 g/ml leupeptin, 1 mM orthovanadate, 1% Triton-X100). Bone marrow samples used for analysis were restricted to those with Ͼ40% blast cells in the diagnostic aspirate, or with у40% following further enrichment of the mononuclear cell isolation on the gradient. Aliquots of cell (10-20 × 10 6 ) were cryopreserved in medium with 20% calf serum plus 10% DMSO and retrieved for assay of drug efflux or drug sensitivity.
Mammalian expression vectors
The dominant-negative c-jun expression plasmid, pLHC mutant c-jun (S63A, S73A), encoding c-jun which is nonphosphorylatable by JNK, due to mutation of serines 63, 73 to alanine, was described previously. 29 The control vector, pLHCX without cDNA insert, like pLHCmutant c-jun, confers hygromycin resistance upon stably transfected cells. These vectors were linearized by restriction enzyme digestion, and individually transfected by electroporation into HL-60/ADR cells by a method previously described. 30 The resulting transfectant cells were placed into McCoy's medium supplemented with hygromycin, 250 g/ml, along with recombinant GM-CSF, 100 ng/ml, for a period of 1-1.5 weeks, and then the cell lines were passaged in the same medium with hygromycin, with or without GM-CSF.
Antibodies
The following antibodies were used for immunoblotting of proteins which had been Western-transferred on to nitrocellulose filters after SDS-PAGE electrophoresis: anti-c-jun/AP-1 (N), obtained from Santa Cruz Biotechnology, Santa Cruz, CA, USA; anti-phopho serine 73-jun, Upstate Biotechnology, Lake Placid, NY, USA; anti-c-jun, New England Nuclear, Boston, MA, USA; anti-GST (P1), Calbiochem, San Diego, CA, USA; anti-catalase, Biomol, Plymouth Meeting, PA, USA; anti-rabbit 
Immunoblotting
Cytosolic proteins were resolved on 12% SDS polyacrylamide gels and transferred to a nitrocellulose filter by a semi-dry Western blotting method (BioRad, Hercules, CA, USA). The technique for immunoblotting has been described. 30 The blots were stripped according to the manufacturer's protocol (Amersham) and subsequently reprobed with the remaining antibodies.
Kinase assay of JNK
Proteins (25-200 g) were incubated with 2 g of a GST fusion protein of the N-terminal region of c-jun (amino acids 5-89) coupled to agarose beads. These reactants were brought to a final volume of 50 l in a phosphotyrosine lysis buffer and incubated with gentle rocking at 4°C for 5 h to allow binding of endogenous JNK to substrate protein as described (solid-phase assay). 26 This mixture was washed extensively by pelleting and resuspension, and the beads were finally resuspended in 10 l distilled water. Next, 20 l of 2 × kinase buffer containing 50 Ci/ml 32P-gamma-ATP (1 Ci per reaction) was added, and the reaction was incubated at 30°C for 20 min. In some experiments, cell lysates were first immunoprecipitated with anti-JNK coupled to protein A, and then immune precipitates were washed and immune complex kinase assays were performed with substrate. The reactions were stopped by adding 2 × volume of Laemmli sample buffer (BioRad) and the reaction contents were boiled and electrophoresed on 12% SDS polyacrylamide gels. The gel was then dried and subjected to autoradiography. Control reactions were performed with GST-coated beads or with a mutant GSTc-jun (5-89) with serines 63,73 converted to leucine. 31 
Analysis of drug sensitivity
Sensitivity of cells to the drug of interest was tested by direct viability counting after 48 h exposure in culture, as well as by an automated tritiated thymidine incorporation protocol involving cells cultured in microtiter plates and incubated for the same period. For the former assay, HL-60 or HL-60/ADR cells were washed and suspended at 10 5 cells/ml in 2 ml McCoy's medium, with or without GM-CSF, 50 ng/ml, in duplicate wells of a 24-well plate (Costar, Corning, NY, USA). To these wells various dilutions of daunorubicin/daunomycin, cytarabine, N-acetylcysteine or tertbutylhydroperoxide (all from Sigma, St Louis, MO, USA) were added. After 48 h, cells in each well were resuspended and counted by trypan blue staining. For the latter assay, replicate wells (between three and six) of a 96-well microtiter plate (Costar) were plated with SPOTLIGHT serial two-fold dilutions of the above compounds into medium containing 5 × 10 4 cells in a total volume of 100 l, and after 48-h incubation, 1 Ci/well of 3 H-thymidine was added for 18 h and then the plates were harvested after hypotonic lysis on to glass fiber strips using a multiple automated sample harvester (PHD cell harvester; Cambridge Technologies, Cambridge, MA, USA). The filter discs were suspended in liquid scintillation cocktail and counted. Viabilities or thymidine incorporation data were plotted as mean ± s.e.m.) vs drug concentration over a logarithmic scale, from which the population lethal concentration 50 was established.
Calcein AM efflux assay
This assay bears the capacity for monitoring MRP-mediated efflux and/or Mdr1-mediated efflux and has been tightly correlated with expression levels of pgp-170/mdr1 protein and MRP protein. 3 Cell lines or primary leukemia cells removed from cryopreservation by overnight culture were first washed with HBSS supplemented with 10% FCS and then placed at 1 × 10 6 /ml in warm RPMI supplemented with 10% FCS. Cells were loaded with 0.1 g/ml with calcein AM, without or with cyclosporin 1 M, in this medium for 30 min at 37°C, and then washed with HBSS/10% FCS, and resuspended. In the samples to serve for analysis of cyclosporin-inhibitable calcein AM exclusion (mdr1 pump), the control or the cyclosporintreated samples were resuspended in control RPMI and analysed by FACS analysis at 535 nm for fluorescence intensity. For analysis of MRP-mediated efflux, cells loaded with calcein AM were washed and duplicate samples were placed in warm RPMI/10% FCS with probenecid, 2 mM, and reincubated at
Figure 1
Comparable activities for JNK in blast cells of primary AML with certain model cell lines. Lysates of the cell lines: HL-60, HL-60/ADR and K562 were prepared and placed into assay with agarose beads bound with GST-c-jun substrate. Alongside, lysates prepared from primary blasts of AML cases 2306, 2135, 2210, and 2301 were placed into assay at the same concentrations. The reaction contents were subjected to SDS-PAGE and autoradiographed.
Leukemia time points of 0, 15, 30, 60 min. Then control and probenecid-treated samples were washed and resuspended in cold RPMI/10% FCS and analyzed for fluorescence intensity as noted above. Efflux occurred when time-dependent diminished calcein fluorescence was demonstrated, which was reversed by probenecid. For the calculation of efflux as a continuous variable, the ratio of calcein efflux of cells was determined as the mean channel fluorescence after incubation in the presence of probenicid divided by the calcein efflux after incubation in the absence of probenicid (after accounting for any significant differences in background fluorescence). This calculation gave an efflux number which was cognate positive with a value greater than 1.
Statistical analysis of biochemical variables associated with blasts from leukemia cases
Mononuclear blast cells were isolated from 67 diagnostic marrows as noted, and analysis was undertaken on lysates from freshly isolated cells. Initially, this involved immunoblotting for c-jun and kinase assay of JNK. After experience was gained with these assays in more than 50 samples, and a clear statistical correlation was noted, the phospho-c-jun antibody became available. It was validated for its ability to mirror the activity of JNK in 14 cases (concordance 12/14 with JNK, total concordance with c-jun). Thereafter, analysis was limited to phospho-serine 73 c-jun, and correlations were undertaken of the clinical outcomes using the aggregate definitions of JNK activity. Analysis of the association of JNK with: (1) c-jun; (2) cytogenetic risk category (good, intermediate, poor); and with (3) outcome (complete remission or initial failure/failure within 3 months) was performed by a two-sided chi-square test. For the variable of presenting WBC blasts, correlation with JNK activity was performed by two-sided t-test, after log transformation of WBC counts per microliter volume of blood. Statistical analysis of results of efflux was examined in terms of efflux as a continuous variable. Spearman's coefficient of rank correlation was calculated between all continuous variables with sufficient numbers of observations because this does not require the assumption of a bivariate normal distribution. For each continuous response variable, the Wilcoxon two-sample test was used to test for differences in medians between the two groups for each categorical variable. 
Fluorescence detection of MRP1/MDR1 expression

Results
HL-60/ADR, an anthracycline resistant variant of HL-60, expresses increased activity of JNK and levels of c-jun protein: comparable activity within primary AML blasts
Previously we reported that murine and human cell lines with p210 Bcr-Abl, as well as primary human leukemia cells with
Figure 2
Stability of JNK activity within AML blasts over a range of protein concentrations, and in tissue culture. Cytosols derived from patients with constitutive JNK activity (patients 1, 7) vs a patient without constitutive JNK activity (No. 5) were prepared from marrow blasts, either immediately after isolation from the patient, or after placement in tissue culture medium (McCoy's 10% FCS) either in the presence or absence of GM-CSF. The time zero samples were tested in the reaction over a range of protein concentrations to demonstrate relative invariance of activity within a 10-fold range of protein. In those samples tested at time zero and after overnight culture, the same activity was seen before and after culture.
the Philadelphia chromosome product, both exhibited constitutive activity of c-jun N-terminal kinase and expressed abundant c-jun protein. 31 We queried whether a broader range of myeloid leukemias, categorized either on the basis of functional resistance to standard induction chemotherapy treatments delivered to patients, or by traditional pathologic/morphologic type, might segregate into categories of JNK activity status. First, the activity of JNK was measured within lysates of the positive-control K562 cell line, within a negative-control Ph-negative leukemia cell line HL-60 ( Figure  1) . To pursue the possible involvement of JNK in multidrug resistance, these results for JNK activity (strong in K562, absent in HL-60) were compared to those obtained within HL-60/ADR, an adriamycin-resistant cell line variant of HL-60 ( Figure 1 ). In addition, various morphologic subtypes of primary (de novo and relapsed) human AML blasts were studied for the activity of JNK. These reactions were performed simultaneously with the control cell lines. The reaction mixtures were electrophoresed and submitted to autoradiography ( Figure 1 ). As noted before, K562 lysates had abundant JNK activity ( Figure 1 ). The activity of HL-60/ADR cells was of comparable magnitude in a series of experiments, whereas HL-60 was lacking this activity ( Figure 1 ). On the other hand, lysates of fresh human AML blasts from patients differed in the level of JNK activity relative to the strong positive cell line controls, K562 and HL-60/ADR, vs the negative control HL-60 ( Figure 1) . Roughly 50% of individuals demonstrated strong activity of JNK among a large series of cases (see below). The magnitude of activity, when present, was comparable to the cell line controls (Figure 1 ).
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In order to determine whether the results obtained with patient samples reflected a stable phenotype of the particular leukemic blasts, and did not simply reflect the processing of samples, and to ensure the stability of these results, the JNK assay was repeated following several test manipulations in the assay for the purpose of standardization. On those samples registering positive-and negative-activity results in the initial screening assay, we extended their analysis by looking at a range of lysate protein concentrations in the assay. This was done to establish whether the result observed was a stable characteristic of the lysate rather than a phenomenon subject to drastic variation by dilution to suboptimal lysate concentrations. Also placed into assay were lysates prepared from leukemia cell samples that had been cryopreserved and then thawed and cultured overnight either in the presence of medium supplemented with FCS alone, vs the same medium supplemented further with recombinant GM-CSF, 50 ng/ml. Representative results of such experiments are shown ( Figure 2 ).
In fact, from patient samples that had previously registered either positive (patient 7) or negative (patient 5) in the JNK assay, stability of results was observed over a range of input protein concentrations of lysate from 25-200 g (Figure 2 ). Also, stable JNK activity status was observed after overnight culture in either medium alone or medium supplemented with
Figure 3
Correspondence between JNK activity status of HL-60 vs HL-60/ADR, with expression of c-jun and phosphoserine 73-c-jun. Cell lysates from HL-60 and HL-60/ADR were immunoblotted for cjun, phospho-serine 73 c-jun, then GAPDH to serve as a loading control. Note correspondence with JNK activity (Figure 1 ).
Leukemia
Figure 4
Hyperexpression of nonphosphorylatable c-jun mutant (S63, 73A) in HL-60/ADR + JNP cells. Equal amounts of lysates of HL-60, HL-60/ADR, vs HL-60/ADR + JNP were subjected to SDS-PAGE electrophoresis, Western transfer, then were immunoblotted sequentially for c-jun, phospho-serine-73 c-jun, and GAPDH, a loading control.
Figure 5
No loss of JNK enzyme activity in HL-60/ADR cells expressing JNP. Equal amounts of lysates of the cell lines HL-60/ADR, HL-60, or HL-60/ADR + JNP (maintained under either of two different culture conditions, with or without GM-CSF) were placed into the JNK assay and subjected to SDS-PAGE. Then the gel was autoradiographed.
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Leukemia GM-CSF (Figure 2 ). In addition, in a series of seven experiments (not shown) we obtained duplicate marrow samples and from one duplicate we harvested mononuclear cells immediately and prepared cell lysates, or in the other, prepared lystes after resting the whole marrow sample on the benchtop overnight and then processing the next morning. This was done to establish whether the JNK activity status was subject to a labile intermediate or might be the target of phosphatase activity. Complete concordance of JNK activity status was observed comparing the samples processed at different times, consistent with a stable phenotype (data not shown). Also, lysates from leukemic blasts obtained from certain individual patients at different times of progression of a nonremission state demonstrated concordance of JNK activity over time (data not shown).
Next, lysates were examined by immunoblotting for expression of c-jun protein. First, we immunoblotted lysates of HL-60 vs HL-60/ADR, and observed a correlation between JNK enzyme activity and expression of c-jun protein ( Figure  3 ). HL-60/ADR cells with high JNK activity also expressed abundant c-jun protein; but parental HL-60 cells were essentially devoid of c-jun (Figure 3) . Thus, as reported by others, JNK enzyme activity for N-terminal c-jun was an important determinant in driving c-jun's own expression by transcriptional activity on its own promoter. Next, the abundance of serine-73 phosphorylated c-jun was specifically examined to document the expected phosphorylated product of JNK's activity (Figure 3) . Equivalence of protein loading on the gel/blot was demonstrated by reprobing the blot for GAPDH, a constitutive protein in these cells (Figure 3 ). 
Interrruption of JNK signaling by nonphosphorylatable c-jun (JNP) reverses multidrug resistance of HL-60/ADR as it confers hypoexpression of transcriptional targets, including MRP1
Preliminary experiments verified the marked difference in sensitivity to daunorubicin/daunomycin between HL-60/ADR and HL-60 (data not shown, see below). In order to extend to a functional level the association between activity of JNK and c-jun expression with drug resistance in HL-60/ADR vs HL-60, we devised to disrupt the signal transmission between the enzyme JNK and its substrate, the transcriptional effector pro-
Figure 6
Cell recovery assay reveals marked differences in lethal concentrations for 50% of populations (LC 50 ) between HL-60 vs HL-60/ADR; and expression of DN c-jun (JNP) markedly reduces LC 50 in HL-60/ADR. (a) Duplicate wells were plated for the cell lines HL-60 (!), HL-60/ADR (⌬), and HL-60/ADR + JNP (?) in medium (McCoy's 10% FCS plus 50 ng/ml GM-CSF) without or with daunorubicin 2.5 g/ml, 1 g/ml, 0.5 g/ml, 0.25 g/ml, and 0.1 g/ml. At 48 h, cell recovery by trypan blue counting was peformed and the mean viable cell recovery ± s.e.m. was plotted. Note extreme sensitivity of HL-60 cells (LC 100 Ͻ0.1 g/ml), the extreme resistance of HL-60/ADR (LC 50 1.25 g/ml), and the sensitivity of HL-60/ADR + JNP (LC 50 0.1 g/ml). 
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tein, c-jun. Therefore the strategy adopted was to overexpress within HL-60/ADR cells dominant-negative full-length c-jun, which has the normal high affinity docking site for JNK that characterizes c-jun, but lacks target serines 63, 73 (converted to alanine, and thus, nonphosphorylatable): pLHmutant c-jun (S63A, S73A) or JNP.
HL-60/ADR cells were transfected with the JNP vector, then selected in medium with hygromycin (resistance encoded in the vector) and when a stable cell line was generated, analysis was performed for the expression of JNP (Figure 4) . The strategy involved analysis by immunoblot of the relative level of cjun vs phosphoserine-73 c-jun between HL-60/ADR and HL-60/ADR+JNP (Figure 4) . In fact, HL-60/ADR+JNP cell line overexpressed c-jun protein compared with HL-60/ADR. The amount of this c-jun protein which was detectable with antibody against phosphoserine-73 was less than in HL-60/ADR, confirming the excess production of the nonphosphorylatable c-jun (Figure 4 ).
Figure 7
Multidrug resistant HL-60/ADR cells have marked difference in inhibitory concentration 50 (IC 50 ) from HL-60 or HL-60/ADR + JNP for daunorubicin, but not for cytosine arabinoside (Ara-C). Six replicated microwells of each cell line were plated into 96-well microtiter plates without (bars) or with a range of concentrations of daunorubicin/daunomycin or Ara-C (symbols). Then tritiated thymidine 0.5 Ci/well was added after 36 h and the wells were harvested and counted at 48 h. Data reported as mean c.p.m. ± s.e.m.
Leukemia
In order to confirm that introduction of JNP into HL-60/ADR had not affected activity of JNK, we performed JNK assays for HL-60/ADR+JNP grown in medium or medium plus GM-CSF with the parental cell lines assayed before. No effect of JNP on enzyme activity of JNK was observed within HL-60/ADR cells ( Figure 5) .
In order to determine the effect of JNP on the difference in daunomycin sensitivity between HL-60 and HL-60/ADR, both cell recovery assays and proliferation assays were performed over one or more base-10 logarithms of drug concentration. Results of concentration-dependent cell killing expressed as cell recovery vs daunomycin concentration demonstrated that total cell killing of HL-60 cells occurred at the lowest concentration of daunomycin tested (0.1 g/ml), whereas in HL-60/ADR this same dose of daunomycin was totally ineffective at cell killing ( Figure 6) . Further, at the maximum concen- 
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tration of daunomycin of 2.5 g/ml, there was approximately 30% survival of HL-60/ADR, and a lethal concentration for 50% of HL-60/ADR cells (LC 50 ) was on the order of 1 g/ml ( Figure 6 ). By contrast, in the HL-60/ADR+JNP cells, the survival of 50% of the population was not reached until the daunomycin concentration had been reduced to 0.1 g/ml, and less than 1% of the population survived the maximal daunomycin concentration (Figure 6 ). The same logarithm-10 difference in LC 50 s observed when comparing HL-60/ADR vs HL-60/ADR+JNP by viable cell recovery was also observed when comparing HL-60/ADR transfected with empty control vector (HL-60/ADR+pLHCX) with those cells expressing dominantnegative c-jun, JNP ( Figure 6 ).
Next, thymidine incorporation assay was used to determine if the sensitivity of HL-60, HL-60/ADR, and HL-60/ADR +JNP to cytosine arabinoside (Ara-C), a selective inhibitor of DNA synthesis, was similar, or whether, in fact, JNK and c-jun are less important for determining sensitivity to a drug which is not subject to ABC-pump efflux and does not directly induce redox stress. The capacity for proliferation of HL-60/ADR vs HL-60/ADR + JNP in response to graded doses of Ara-C was superimposable. HL-60 was less sensitive to Ara-C, but this does not appear to be significant ( Figure 7) . Thus, the effect of JNK and c-jun on daunomycin sensitivity was a unique association.
In further pursuit of the multidrug resistance state defined by response to daunorubicin, cell lysates were immunoblotted for two potential candidate gene products involved in redox homeostasis and cellular detoxification and/or efflux, whose
Figure 10
Immunofluorescence detection of expression of MRP1 and p-glycoprotein/mdr1 in leukemia samples. Blast cells from leukemia cases 2398, 2350, and 2399 were either stained for detection of MRP1 (left) or p-glycoprotein/mdr1 by the protocol described in Materials and methods. Specific fluorescence intensity for the aforementioned antibodies is pictured in red, whereas background staining with nonspecific antibody control is pictured in the open contour, with fluorescence intensity on the abcissa and events on the ordinate. In the pictured studies, the MRP1 fluorescence rank ratios (mean channel fluorescence with specific antibody/control antibody mean channel fluorescence) were 1.4, 1.4 and 1.3 for cases 2398, 2350 and 2399, respectively. The fluorescence rank values for p-glycoprotein for these same respective samples were 2.1, 1.3 and 1.0.
Leukemia transcriptional control has previously been linked to c-jun/AP-1: catalase and GST- (Figure 8 ). In fact, HL-60/ADR cells with JNP had significant reduction compared to HL-60/ADR in expression of both catalase and GST-when controlled for loading on the gel by reprobing the blot for GADPH (Figure 8 ).
The impact of these reductions in GST and catalase appears to be reflected in the enhanced sensitivity to daunorubicin conferred by JNP transduction demonstrated above. Secondly, oxidative stress homeostasis within HL-60/ADR vs HL-60/ADR + JNP cells was directly tested using tertbutylhydroperoxide (TBH), and we also performed addition of N-acetylcysteine, an antioxidant, to rescue cells from the toxicity of daunorubicin. Although only a narrow dose window separating the killing of cells vs non-toxicity was observed using the TBH reagent, HL-60/ADR + JNP cells had 47 ± 15% cell kill upon exposure to 25 M TBH vs 24 ± 8% killing of HL-60/ADR (mean ± s.e.m., four experiments). Also, addition of NAC, 5 mM raised the LC 50 for daunorubicin within HL-60/ADR + JNP cells from 0.28 M to 0.41 M.
In addition, the potential contribution of JNP toward inhibition of MRP efflux was tested. MRP-specific cellular efflux assays were performed using the model substrate calcein AM. MRP-specific efflux was a property of HL-60/ADR as demonstrated by time-dependent loss of fluorescence of the dye loaded within cells, and this effflux was inhibited by probenecid (Figure 9a ). On the other hand, MRP-specific efflux was not a property of parental HL-60 cells, and the HL-60/ADR + JNP cells had lost their capacity to efflux calcein-AM ( Figure  9a ). We also found that MRP1 protein expression, a feature
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Leukemia of HL-60/ADR cells, was lost in the HL-60/ADR cells expressing JNP, as studied by immunofluorescence (Figure 9b ). On the other hand, unlike HL-60/VCR cells which express abundant p-glycoprotein/mdr1 protein, HL-60/ADR cells expressed modest or insignificant levels of p-glycoprotein/mdr1 ( Figure  9c ).
Correlation of JNK activity and c-jun expression, with serine 73 phosphorylation of c-jun, expression of catalase and GST, and MRP-mediated efflux in individual primary AML cases: association with clinical attributes
A total of 67 individual samples of primary marrow blast cells derived from patients with AML were studied. These were subjected to analysis of their lysates for enzyme activity of JNK and for c-jun expression by immunoblot, in order to establish the validity of correlating clinical parameters in the patients with functional, biochemical attributes of the blast cells composing the individual cases. There was an 85% rate of correspondence between occurrence of constitutive JNK enzyme activity and presence of c-jun on immunoblot, or of the
Figure 11
Correlation of expression of c-jun, phosphoserine 73 cjun, GST, and catalase in acute myeloid leukemia blasts. HL-60, HL-60/ADR cells, as well as primary blast cells from AML cases 2385, 2386, 2394, 2395, 2398, 2399, 2400, were sequentially immunoblotted for c-jun, ser73phospho-c-jun, GST, catalase, then GAPDH. Lowest content of JNK effectors was noted in case 2385 (achieved remission), whereas the case with the highest content of the effectors, 2398 failed to achieve remission with intensive therapy.
absence of both (P Ͻ 0.001) ( Table 1) . Of these, exactly 50% of the cases exhibited constitutive JNK activity. Indeed, this patient cohort consisted of a skewed population of cases which were considered high risk disease (at least 50% were secondary or relapsed leukemia) and half of the cases were also considered elderly (Ͼ55 years). With these baseline demographic characteristics, analysis of clinical parameters in relation to JNK activity/c-jun expression demonstrated a strong correlation between JNK activity and the presence of a high presenting WBC count (analysis as a continuous variable, P = 0.003, n = 67, WBC mean 2.5 times in JNK+ve, Table 1 ).
In addition, there was a strong association between the presence of JNK activity and failure of response (relapse within 3 months or primary nonresponsiveness, in aggregate) (P = 0.046, n = 64, Table 1 ), but there was not a statistically significant association between JNK and a particular cytogenetic risk category (P = 0.079, n = 57).
More in-depth analysis was undertaken of the signaling cascade represented by JNK activity for serine phosphorylation of c-jun serine 73, augmented expression of c-jun/AP-1-dependent target genes catalase and GST , and also MRPmediated efflux, as outlined in the cell line studies, attempting to uncover a paradigm for the multidrug resistance phenotype in the primary AML samples. First, in 33 of the 67 samples subjected to analysis of JNK activity and c-jun expression, MRP-specific efflux studies were performed on cryopreserved cells that were thawed and cultured overnight as noted.
There was general agreement between presence of JNK enzyme activity and the presence of MRP-mediated efflux, reported with calcein efflux ratios as a continuous variable, but the observations did not reach statistical significance on this sample set without further categorization (P = 0.067, n = 33, Table 1 , for illustrations of efflux, see below). However, if a stricter definition of efflux were used, corresponding to a higher degree of calcein efflux within leukemic blasts amounting to Ͼ56% of the HL-60/ADR-positive control cell line evaluated alongside in each analysis, then the dichotomized variables yielded a strict statistical relationship between JNK activity and MRP efflux of blasts (20/21 JNK + /MRP efflux + , P = 0.016, Fisher's exact test of the dichotomized variables) ( Table 2 ). This approach has been taken by SWOG in reporting results of functional efflux. 4 When the outcome of therapy (response) was evaluated in comparison to MRP efflux (reported with calcein efflux ratio as a continuous variable) in this subset of patients in whom efflux studies were possible, no statistical relationship was found (P = 0.49, Wilcoxon test for continuous variable).
Relationships between expression of MRP1 and mdr1/pgp 170 proteins measured by immunofluorescence/FACS scanning were further explored. Almost all of the leukemia samples with constitutive JNK activity expressed significant amounts of MRP1 fluorescence, at levels corresponding to HL-60/ADR control (HL-60/ADR = fluorescence ratio MRPm6/control, 1.9 ± 0.25), but only a subset of these samples had strong expression of mdr1/pgp 170 (MRK16 positivity) (Figure 10 ). There was no correlation between mdr1 expression and response (Wilcoxon test, P = 0.15). Interestingly, neither did MRP1 expression (continuous variable of fluorescence rank) relate statistically to MRP efflux, nor to response to therapy.
Next, multiparameter immunoblotting was undertaken for primary AML samples, looking for a correlation between hyperexpression of putative c-jun target proteins (GST and catalase) with c-jun and phospho-serine 73 c-jun abundance (Figure 11 ). This blot demonstrated that hyperexpression of
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GST and catalase was most closely linked with abundance of phospho-serine 73 c-jun (Figure 11 ). Interestingly, case No. 2385 was a good prognosis variant AML/M4eos subtype of the French-American-British classification scheme with absent JNK activity, along with absent c-jun and phospho-cjun, and with markedly diminished expression of GST and catalase. In the other cases studied, there was a strong association between hyperexpression of phospho-c-jun, GST, and catalase ( Figure 11 ).
Another panel of samples was also immunoblotted for phosphoserine-73-c-jun and was subjected to evaluation of MRPmediated efflux (Figure 12 ). Cells from cases 2335 and 2350 expressed very abundant phosphoserine-73 c-jun and exhibited the most robust MRP-mediated efflux observed in all analyses performed, at levels comparable to the HL-60/ADR cell line control ( Figure 12 and data not shown). Case 2353 was a rare Philadelphia chromosome-positive AML whose blasts expressed very abundant phosphoserine-73 c-jun and exhibited efflux ( Figure 12 ).
Interestingly, case 2354 was, like 2385, a FAB-type AML M4Eos, but unlike case 2385, 2354 cells expressed phosphoc-jun and exhibited the same degree of MRP-mediated efflux as 2353. Indeed, all these positive samples, 2350, 2353, 2354, met the criterion established of Ͼ56% of HL-60/ADR control fractional efflux ( Figure 12 ). In summary, JNK activity in AML is associated with abundance of phosphoserine-73 c-jun expression and is an important controlling factor for effector protein functions relevant to treatment failure in AML, with which it is statistically linked in a population study.
Discussion
Two functional paradigms have existed for understanding multidrug resistance in AML: function and expression of pglycoprotein/mdr1 or function and expression of MRP1 ( or MRP1 along with p-glycoprotein). Either situation has been found to describe poor prognosis to standard induction chemotherapy involving the anthracycline drug class in certain patient studies. [2] [3] [4] 32 However, the factors which dictate those patients with one or another of these resistance phenotypes have been poorly understood. First, chromosomal amplification of these gene loci, which often explained their expression in in vitro model cell lines selected by continuous drug exposure, likely does not apply to de novo resistance in AML patients. 33 Neither does morphologically defined FAB classification of AML cases adequately explain expression patterns of p-glycoprotein or MRP1, nor their function. 33 Secondly, p53, a guardian of the genome preventing chromosomal duplication, is infrequently mutated or deleted in AML. [34] [35] [36] Recently, it has been further observed that a dynamic upregulation of mdr1 pump function may occur early in the context of primary chemotherapy of AML blasts in vivo. 37 Thus, a flexible and dynamic effector mechanism for expression of multidrug resistance is likely to incorporate a signaling pathway into a transcriptional response output.
Similarly, others have noted coordinate expression of a number of genes along with the MRP pump in the development of a distinctive drug resistant phenotype, and have provided speculation on the role of c-jun/AP-1 in that phenotype. 13, 15 Further studies have proved that such coordinated gene expression, involving ␥-glutamyl cysteine synthase and GST along with MRP1, would have a survival benefit in respect to the damage incurred within cells exposed to anthraLeukemia cyclines. 15, 16 In the present study, we directly posed the proofof-principle question regarding a role for JNK and its phosphorylation-dependent (serines 63,73) activation of transcription by c-jun of effector(s) in the acquired multidrug resistance phenotype of HL-60/ADR myeloid leukemia cells involving the aforementioned species. 1, 16, 38, 39 We observed that overexpression of a dominant-negative (DN) nonphosphorylatable c-jun vector (JNP) resulted in down-regulation of two AP-1-regulated genes previously implicated in forms of multidrug resistance in other systems:
1,14-16,38,40 catalase and GST (Figure 8 ). This appears to be one aspect of the outcome experienced in these cells with regard to their sensitivity to the anthracycline, daunorubicin. Such cells with DN c-jun had 10-fold increased sensitivity to this drug (Figures 6 and 7) .
In addition to a role for GSTs in conjugating xenobiotic drugs with glutathione (GS-X) for efflux by an MRP-dependent mechanism, different GST isoforms have been implicated in a similar detoxification of oxyradical-induced lipid and base intermediates. 14, 16, 41 In fact, there is controversy regarding the need for glutathione modification of anthracyclines for their MRP-mediated efflux, 14 and, therefore, the conjugation and/or efflux of toxic lipid peroxide-intermediates or base propenals occurring in the aftermath of peroxidative stress which anthracyclines incur in cells, may be functional targets of GST in the leukemia cells we studied (Figures 8 and 11) .
Irrespective of the validity of this above interpretation, cells with DN c-jun experienced abrogation of MRP-mediated efflux measured by the dye calcein AM (MRP efflux is specifically inhibited by probenicid 3 ) (Figure 9a ). One proximate cause for loss of MRP efflux function was loss of MRP1 expression measured by immunofluorescence (Figure 9b) .
Having established that JNK interaction with c-jun is crucial to the existence of a multidrug resistance phenotype with MRP functioning alongside GST in a model leukemia, we posed a population-based question regarding such function in primary cells of adult AML. Indeed, we found that JNK activity status within blast cells of individual cases was a stable phenotype, when cells were rested overnight at room temperature or when cultured in vitro in a supportive medium supplemented with 10% FCS, with or without GM-CSF (Figure 2 , and data not shown). We also observed strict correspondence between JNK activity status (+ve vs −ve) and expression of c-jun protein on immunoblot in 58 analytic samples (P Ͻ 0.001). This would be expected because an important transcriptional regulator for c-jun is c-jun itself, which would be activated for transcriptional function by JNK. 42 A more direct measure of c-jun's role as a transcriptional regulator of target genes with c-jun/AP-1 regulatory motifs would be phosphoserine-73-c-jun, as evidenced by overexpression of the dominant-negative nonphosphorylatable cjun (JNP) in HL-60/ADR + JNP cells, which down-regulated GST and catalase ( Figure 8 , and Refs 1 and 38); as well as MRP-specific efflux function in these model cells (Figure 9 ). The clinical study validated the relationship between constitutive JNK activity and exuberant MRP-mediated efflux, of a magnitude similar to that observed in the control cell line HL-60/ADR (Table 2 ). This appears to explain, in part, the impact of constitutive JNK on treatment failure (Table 1) . However, in concert with these statistically validated observations, one may postulate that GST hyperexpression may play a supportive role.
In the subset of our samples which could be subjected to fluorescence detection of MRP1, MRP1 expression itself did not correlate with MRP efflux function (P = 0.911, data not shown). This leads to the postulate that patient prognosis may
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Leukemia be related to MRP1 functioning cooperatively with other effectors under the control of JNK, whose relationship with prognosis was established (Table 1) . In fact, others have observed that MRP function, but not MRP1 expression, correlates with prognosis, and this may reflect the requirement of a constellation of coordinate effectors, possibly subject to JNK/c-jun regulation as we have suggested here. 16 It was also of interest that of those AML samples in which MRP1 and mdr1/p-glycoprotein expression could be studied, there was no correlation between expression of the two ABC-cassette pumps (data not shown). Indeed, despite extreme sensitivity for detecting expression of p-glycoprotein in our samples reflected with
Figure 12
Close correspondence between expression of phosphoserine 73-c-jun in acute myeloid leukemia cases with ability for MRPmediated efflux. (a) MRP-mediated efflux of calcein AM dye was studied in leukemia cases 2350, 2353 and 2354, along with the control negative activity cell line (HL-60), and with the positive activity control cell line HL-60/ADR. Same protocol for probenecid inhibition of efflux was used to demonstrate the nature of positive activity. Relatively equal magnitude of 2335 compared with 2350 was observed, as was relatively equal activity of 2386 with 2354. On the other hand, case 2385 showed absent activity for MRP-mediated efflux despite being the same FABtype as 2354. However, these cases differed in the expression of phosphoserine 73-c-jun. simultaneous performance of positive control staining of the cell line HL-60/VCR in each determination, we found little pglycoprotein expression in our patients sampled (mean ± s.d. of test/control antibody-mediated fluorescence: HL-60/VCR, 49.8 ± 19.4 (n = 30) vs AML patients, 1.5 ± 0.6 (n = 30), see Figures 9c and 11) . Thus, the population under study may differ from that reported by others. 2, 4, 32 Of interest regarding our observations on GST hyperexpression in the context of constitutive JNK activity, is the report that cellular monomeric GST is an intrinsic inhibitor of JNK, which dampens JNK activity in the absence of stress in nontransformed cells. 43 Our data seem to indicate that the consti-
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tutive JNK activity of the most virulent AML blasts reflects a state of chronic stress accompanying transformation, in which GST may be oxidized and oligomerized, and unavailable for feedback inhibition (a property specific to the reduced monomer form. Interestingly, we have observed a rare instance of an AML blast lysate with absent JNK activity and absent c-jun protein, with, nevertheless, abundant GST (data not shown). This lysate specifically inhibits the constitutive JNK activity present in the lysates of other strongly positive blasts, as might be expected of the data reported by others. 43 Also of interest in our study was the strong association of constitutive JNK activity with hyperleukocytosis at presentation of disease (Table 1 ). This appears to have foundation in the role of c-jun, activated for transcription by JNK, in repression of basal p53 transcriptional expression, thus ameliorating an oncogene-induced up-regulation of p21cip1. 26, 27 We have not fully determined the profile of oncogenes contributing to strong signaling in the blast cells with constitutive JNK activity, but it appears that mutant Flt3 is a prominent contributor (data not shown, GS Burgess and HS Boswell, 2001) . If this were the dominant factor, our data would provide a mechanistic insight into the functional resistance pathway associated with Flt3 mutation occurring in large population studies of AML. 44, 45 Finally, our data establish the JNK pathway as important for monitoring potential of leukemia cells for functions of xenobiotic efflux via MRP and homeostatic response to oxidative stress, factors contributing to treatment failure in patients.
Note added in proof
The following information became available in the last stages of review of our manuscript and escaped citation. The cited data report the same observations within drug resistant human glioblastoma cells as we report for human AML (Potapova O, Basu S, Mercola D, Holbrook NJ. Protective role for c-jun in the cellular response to DNA damage. J Biol Chem 2001; 276: 28546-28553). That is, c-jun function in the context of its activator, JNK, is important in resistance to anthracyclines, including, daunorubicin and doxorubicin. Human glioblatoma cells with inhibition of JNK using DN c-jun had a reduction in the LC 50 for daunorubicin by approxixmately 100 ng/ml. Leukemia
